Skip to main content
Clinical Trials/CTRI/2021/01/030636
CTRI/2021/01/030636Not yet recruitingPhase 4

Assessment Of Hypoglycemic Effect Using Holistic Approach Of Ayurveda Protocol For The Management Of Prameha/Madhumeha With Special Reference To DM Type 2 Using Different Dosages Pattern: A Therapeutic Clinical Trial - AHHAPMPMDM

All India Institute of Ayurveda0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Patients of either gender in the age group of 25-65years.
  • 2. Patients with classical signs and symptoms of Prameh/Madhumeha viz Prabhuta
  • Mutrata, Avila Mutrata, Pipasadhikya, Alasya, Utsahahani, Kshudhadhikya,
  • Pindikodveshthana, Karapadatala Suptata, Daurbalya, Nidradhikya and
  • Purishabadhdhata.
  • 3. Patients with random blood sugar level (RBS) >200 mg/dl up to 450
  • 4. Fasting blood sugar (FBS) >110 mg/dl up to 300 mg/dl
  • 5. Postprandial blood sugar (PPBS) >140 mg/dl up to 450 mg/dl
  • 6. Glycosylated haemoglobin > 6.5%.
  • 7. Newly /early diagnosed cases to be included as per following criteria:
  • i. Patients who are not taking any conventional medicine for more than two
  • months, whose sugar levels are raised and fall within the inclusive criteria
  • mentioned above and are willing to take Ayurvedic treatment.
  • ii. Patient accidently diagnosed in routine check-up or when appeared with other
  • complaints in the hospital.
  • iii. Early diagnosed diabetic patients (less than 2yr of diabetic history) and not
  • taking any pharmacological drugs since last two months

Exclusion Criteria

  • 1. Patients having insulin dependent DM (type 1) and receiving insulin / OHA
  • 2. Excessive blood glucose: FBS > 300 mg/dl and PPBS > 450 mg/dl
  • 3. Emergency conditions in cases of DM.
  • 4. Patients with acute/chronic liver disease with elevated liver enzymes.
  • 5. Chronic complications like microvascular and macrovascular derangements.
  • 6. Hyperthyroidism or hypothyroidism
  • 7. Patients reporting to be hypersensitive to any of the proposed trial drugs.
  • 8. Pregnant women/ lactating mothers
  • 9. Participation in other clinical studies in past 12 weeks.
  • 10. Takes psychotropic medications that raise blood glucose (e.g. atypical antipsychotics)

Investigators

Similar Trials